It has been observed that the anti-inflammatory tolfenamic acid decreased the expression of hyperphosphorylated tau in the brain by inhibiting GSK-3β activity, decreasing phosphorylated PP2 A, and enhancing PP2 A activity in AD models (Zhang et al. 2020). Here, MAPT is linked to Alzheimer disease.